InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（8 笔）
内部人交易记录
首席执行官已披露买入
0
已披露卖出
8
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the full record of transactions filed by Mackay Martin, 董事. Director active across 6 companies, notably CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Cumulatively, 21 filings have been logged. Breakdown: 0 buy · 8 sells. History available since 7 May 2021. The latest transaction was disclosed on 21 May 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Mackay Martin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报21 总计
20,023 股Common StockSEC:0001104659-25-065304:0
946 股@ US$134.9848.8% 占其流量Common StockSEC:0001127602-25-015485:0
10,060 股0Common StockSEC:0001104659-25-049655:0
9,963 股0Common StockSEC:0001104659-24-083966:0
559 股@ US$228.4151.2% 占其流量Common StockSEC:0001127602-24-015531:0
95 股0Common StockSEC:0001127602-23-019952:0
338 股0Common StockSEC:0001127602-23-017435:0
664 股0Common StockSEC:0001127602-23-015850:0
549 股0Common StockSEC:0001127602-22-014473:0
272,609 股Common StockSEC:0000899243-22-001801:0
63 股0Common StockSEC:0001127602-22-000559:0
355 股0Common StockSEC:0001127602-21-016109:0
11,763 股Common Stock, par value $.0001 per shareSEC:0000899866-16-000239:0
100 股Common Stock, par value $.0001 per shareSEC:0000899866-16-000239:1
362 股Common Stock, par value $.0001 per shareSEC:0000899866-16-000239:2
100 股Common Stock, par value $.0001 per shareSEC:0000899866-16-000239:3
100 股Common Stock, par value $.0001 per shareSEC:0000899866-16-000239:4
400 股Common Stock, par value $.0001 per shareSEC:0000899866-16-000239:5
1,043 股Common Stock, par value $.0001 per shareSEC:0000899866-16-000239:6
58 股Common Stock, par value $.0001 per shareSEC:0000899866-16-000239:7
1,908 股Common Stock, par value $.0001 per shareSEC:0000899866-16-000239:8
21 条申报中的 21 条
About Mackay Martin
MACKAY MARTIN is Administrateur et Directeur Général. He is associated with ALEXION PHARMACEUTICALS INC, Charles River Laboratories International, INC., SpringWorks Therapeutics, Inc. and Rallybio Corp. This declarant has 21 filings in total, and across the 21 sampled filings the period runs from 2016-02-08 to 2025-07-02, with Attribution transactions and buy and sell volumes of EUR 0 and EUR 0.
